Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan. 142(1):46-54.e42; quiz e30. [Medline].
Niemarkt HJ, de Meij TG, van de Velde ME, van der Schee MP, van Goudoever JB, Kramer BW, et al. Necrotizing Enterocolitis: A Clinical Review on Diagnostic Biomarkers and the Role of the Intestinal Microbiota. Inflamm Bowel Dis. 2014 Sep 29. [Medline].
Venter C, Brown T, Meyer R, Walsh J, Shah N, Nowak-Węgrzyn A, et al. Better recognition, diagnosis and management of non-IgE-mediated cow's milk allergy in infancy: iMAP-an international interpretation of the MAP (Milk Allergy in Primary Care) guideline. Clin Transl Allergy. 2017. 7:26. [Medline].
Hourigan SK, Sears CL, Oliva-Hemker M. Clostridium difficile Infection in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr. 22 (4):1020-5. [Medline].
Starr AE, Deeke SA, Ning Z, Chiang CK, Zhang X, Mottawea W, et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC. Gut. 2016 May 23. [Medline].
Higuchi LM and Bousvaros A. Epidemiology and diagnosis of inflammatory bowel disease in children and adolescents. UpToDate. Dec.
Zhi Wei, Steven Baldassano, Hakon Hakonarson. Genetics of Inflammatory Bowel Disease. Petar Mamula, Jonathan E. Markowitz, Robert N. Baldassano. Pediatric Inflammatory Bowel Disease. 2. New York: Springer; 2013. 3-12.
Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011 May. 140(6):1785-94. [Medline].
Koletzko S, Niggemann B, Arato A, Dias JA, Heuschkel R, Husby S. Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI Committee practical guidelines. J Pediatr Gastroenterol Nutr. 2012 Aug. 55(2):221-9. [Medline].
Mooiweer E, van der Meulen AE, van Bodegraven AA, Jansen JM, Mahmmod N, Nijsten J. Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: a retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis. 2013 Nov. 19(12):2603-10. [Medline].
Benchimol EI, Turner D, Mann EH, Thomas KE, Gomes T, McLernon RA. Toxic megacolon in children with inflammatory bowel disease: clinical and radiographic characteristics. Am J Gastroenterol. 2008 Jun. 103(6):1524-31. [Medline].
Mortensen JH, Godskesen LE, Jensen MD, Van Haaften WT, Klinge LG, Olinga P, et al. Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn's Disease from Ulcerative Colitis. J Crohns Colitis. 2015 Jul 17. [Medline].
Douglas D. Biomarkers May Help Differentiate Crohn's From Colitis. Reuters Health Information. Available at http://www.medscape.com/viewarticle/849076. August 06, 2015; Accessed: September 14, 2015.
Reinink AR, Lee TC, Higgins PD. Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis. Inflamm Bowel Dis. 2016 May 19. [Medline].
Rufo PA, Bousvaros A. Challenges and progress in pediatric inflammatory bowel disease. Curr Opin Gastroenterol. 2007 Jul. 23(4):406-12. [Medline].
Escher JC, Taminiau JA, Nieuwenhuis EE, Büller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003 Jan. 9(1):34-58. [Medline].
Zeisler B, Lerer T, Markowitz J, Mack D, Griffiths A, Bousvaros A. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr. 2013 Jan. 56(1):12-8. [Medline].
Sidoroff M, Kolho KL. Glucocorticoids in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2012 Jul. 47(7):745-50. [Medline].
Bousvaros A. Use of immunomodulators and biologic therapies in children with inflammatory bowel disease. Expert Rev Clin Immunol. 2010 Jul. 6(4):659-66. [Medline].
Thukral C, Travassos WJ, Peppercorn MA. The Role of Antibiotics in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2005 Jun. 8(3):223-228. [Medline].
Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014 Jan. 20(1):21-35. [Medline].
Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010 Feb 26. [Medline].
Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007 Mar. 132(3):863-73; quiz 1165-6. [Medline].
Sherlock ME, Griffiths AM. Medical therapy for pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2012 Apr. 14(2):166-73. [Medline].
Rosh JR, Lerer T, Markowitz J, Goli SR, Mamula P, Noe JD. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol. 2009 Dec. 104(12):3042-9. [Medline].
de Bie CI, Escher JC, de Ridder L. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2012 May. 18(5):985-1002. [Medline].
Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. Apr 15 2010. 362(15):1383-95.
Hyams JS, Davis S, Mack DR, et al. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. Lancet Gastroenterol Hepatol. 2017 Sep 19. [Medline].
Baldassarre ME, Laforgia N, Fanelli M, Laneve A, Grosso R, Lifschitz C. Lactobacillus GG improves recovery in infants with blood in the stools and presumptive allergic colitis compared with extensively hydrolyzed formula alone. J Pediatr. 2010 Mar. 156(3):397-401. [Medline].
Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007 Jan 24. CD000542. [Medline].
Raval MV, Hall NJ, Pierro A, Moss RL. Evidence-based prevention and surgical treatment of necrotizing enterocolitis-a review of randomized controlled trials. Semin Pediatr Surg. 2013 May. 22(2):117-21. [Medline].
Ross H, Steele SR, Varma M, Dykes S, Cima R, Buie WD. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum. 2014 Jan. 57(1):5-22. [Medline].
Devaraj B, Kaiser AM. Surgical Management of Ulcerative Colitis in the Era of Biologicals. Inflamm Bowel Dis. 2014 Sep 16. [Medline].
Pakarinen MP, Natunen J, Ashorn M, Koivusalo A, Turunen P, Rintala RJ, et al. Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics. 2009 May. 123(5):1377-82. [Medline].
Floch MH, Walker WA, Madsen K, Sanders ME, Macfarlane GT, Flint HJ, et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol. 2011 Nov. 45 Suppl:S168-71. [Medline].
Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol. 2014 Sep. 12(9):1494-502.e1. [Medline].
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun. 150 (7):1568-78. [Medline].
Kawashima K et al. Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol. April 12 2016.
Lee D, Albenberg L, Compher C, Baldassano R, Piccoli D, Lewis JD, et al. Diet in the Pathogenesis and Treatment of Inflammatory Bowel Disease. Gastroenterology. May 2015. [Medline].